Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 MUTATION
ERBB2 MUTATION - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- 16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of these 16 patients, 14 had known-activating mutations and 2 had mutations of unknown significance. Five of the 16 patients achieved clinical benefit including 1 complete response (6%), 1 partial response (6%) and 3 with stable disease >24 weeks (19%). Clinical benefit was observed across different HER2 mutations including L755S, V777_G778 insGSP, P780_Y781 insGSP, V842I, S310F, and L869R.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5338
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/666
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Breast Cancer
- Evidence Direction
- Supports
- Drug
- Neratinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28679771
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Neratinib | Sensitivity | true |